Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers

Celyad Provides Clinical Update and Strategic Outlook for 2018

Celyad Provides Clinical Update and Strategic Outlook for 2018

Letter to Shareholders - December 2017

Letter to Shareholders - December 2017

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Conference call - Update on Clinical Strategy

Conference call - Update on Clinical Strategy

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Conference call Celyad first half 2017

Conference call Celyad first half 2017

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad Reports First Half 2017 Financial Results and Operational Progress

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces initiation of the SHRINK trial

Celyad announces initiation of the SHRINK trial